Accéder au contenu
Merck

ZDHHC9 promotes colon tumor growth by inhibiting effector T cells.

Oncology letters (2022-11-25)
Xiaodan Chong, Lingxi Zhu, Dong Yu, Shasha Chen, Guang Wang, Qingzhuo Yu, Xianwei Ma, Jing Xu, Haitao Chen, Huazhang An
RÉSUMÉ

Zinc finger DHHC-type palmitoyltransferase 9 (ZDHHC9) has been reported to play an important role in the occurrence and development of several types of cancer. However, its effects on colon cancer growth remain unclear. Using Gene Expression Profiling Interactive Analysis and Tumor Immune Estimation Resource, data obtained from The Cancer Genome Atlas were analyzed, and the results showed that ZDHHC9 was highly expressed in colon cancer and that patients with higher ZDHHC9 expression levels had a worse prognosis. Inhibition of ZDHHC9 expression promoted the proliferation of colon cancer cells in vitro but decreased their growth in vivo. Additionally, inhibition of ZDHHC9 expression in cancer cells enhanced CD8+ T cell-mediated cytotoxicity in vitro and increased CD8+ T infiltration and activation in vivo. Furthermore, ZDHHC9 promoted IFN-γ-induced JAK/STAT1 activation and upregulated programmed death-ligand 1 (PD-L1) expression in colon cancer cells. In conclusion, the present findings showed that ZDHHC9 promoted colon cancer growth by upregulating the expression of PD-L1 and inhibiting the function of CD8+ T cells.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Monoclonal Anti-GAPDH antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL3266, purified immunoglobulin, buffered aqueous glycerol solution